S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
AMZN   1,790.38 (+0.73%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
F   9.10 (+0.33%)
BAC   30.07 (-0.33%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
AMZN   1,790.38 (+0.73%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
F   9.10 (+0.33%)
BAC   30.07 (-0.33%)
DIS   132.86 (+1.53%)
Log in

Fluidigm Stock Price, News & Analysis (NASDAQ:FLDM)

$4.36
+0.14 (+3.32 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$4.16
Now: $4.36
$4.43
50-Day Range
$4.13
MA: $5.06
$5.76
52-Week Range
$4.03
Now: $4.36
$14.90
Volume169,333 shs
Average Volume657,455 shs
Market Capitalization$302.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:FLDM
CUSIP34385P10
Phone650-266-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$112.96 million
Book Value$1.46 per share

Profitability

Net Income$-59,010,000.00

Miscellaneous

Employees535
Market Cap$302.58 million
Next Earnings Date11/5/2019 (Confirmed)
OptionableOptionable

Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter.


Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) released its quarterly earnings results on Thursday, August, 1st. The medical research company reported ($0.20) EPS for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.08. The medical research company earned $28.20 million during the quarter, compared to analysts' expectations of $30.16 million. Fluidigm had a negative return on equity of 31.45% and a negative net margin of 57.48%. Fluidigm's revenue was up 6.8% on a year-over-year basis. View Fluidigm's Earnings History.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Fluidigm.

How can I listen to Fluidigm's earnings call?

Fluidigm will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Fluidigm issued on next quarter's earnings?

Fluidigm issued an update on its third quarter 2019 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $27-30 million, compared to the consensus revenue estimate of $32.71 million.

What price target have analysts set for FLDM?

4 brokers have issued 1-year price targets for Fluidigm's shares. Their predictions range from $14.00 to $16.00. On average, they anticipate Fluidigm's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 247.2% from the stock's current price. View Analyst Price Targets for Fluidigm.

What is the consensus analysts' recommendation for Fluidigm?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fluidigm.

Has Fluidigm been receiving favorable news coverage?

News articles about FLDM stock have trended negative on Thursday, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Fluidigm earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Fluidigm.

Are investors shorting Fluidigm?

Fluidigm saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,990,000 shares, a drop of 27.1% from the August 30th total of 2,730,000 shares. Based on an average daily volume of 855,500 shares, the short-interest ratio is currently 2.3 days. Approximately 2.9% of the shares of the stock are short sold. View Fluidigm's Current Options Chain.

Who are some of Fluidigm's key competitors?

What other stocks do shareholders of Fluidigm own?

Who are Fluidigm's key executives?

Fluidigm's management team includes the folowing people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 46)
  • Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 63)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 60)
  • Dr. Stephen R. Quake, Co-Founder & Chairman of Advisory Board

Who are Fluidigm's major shareholders?

Fluidigm's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.30%) and Nisa Investment Advisors LLC (0.03%). Company insiders that own Fluidigm stock include Levin Capital Strategies, LP, Levin Easterly Partners Llc, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite. View Institutional Ownership Trends for Fluidigm.

Which major investors are selling Fluidigm stock?

FLDM stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have sold Fluidigm company stock in the last year include Levin Easterly Partners Llc and Nicolas Barthelemy. View Insider Buying and Selling for Fluidigm.

Which major investors are buying Fluidigm stock?

FLDM stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Samuel D Colella and Stephen Christopher Linthwaite. View Insider Buying and Selling for Fluidigm.

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $4.32.

How big of a company is Fluidigm?

Fluidigm has a market capitalization of $299.81 million and generates $112.96 million in revenue each year. The medical research company earns $-59,010,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Fluidigm employs 535 workers across the globe.View Additional Information About Fluidigm.

What is Fluidigm's official website?

The official website for Fluidigm is http://www.fluidigm.com/.

How can I contact Fluidigm?

Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000 or via email at [email protected]


MarketBeat Community Rating for Fluidigm (NASDAQ FLDM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  474 (Vote Outperform)
Underperform Votes:  295 (Vote Underperform)
Total Votes:  769
MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel